Other languages COMPASS Pathways plc

Equities

CMPS

US20451W1018

Real-time Estimate Cboe BZX Other stock markets 04:00:33 2024-05-03 pm EDT			5-day change	1st Jan Change
8.42 ^USD	+2.06%		+7.43%	-2.51%

Apr. 29	Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression	CI
Apr. 18	Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression	Apr. 29
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	Apr. 18
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	Apr. 18
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	Apr. 02
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	Apr. 02
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	Apr. 01
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	Apr. 01
Compass Pathways Co-Founders Step Down From Board; David Norton Named Interim Chair; Shares Fall	Mar. 28
COMPASS Pathways plc Announces Board Changes	Mar. 28
Compass Pathways Insider Sold Shares Worth $704,821, According to a Recent SEC Filing	Mar. 15
Compass Pathways Insider Sold Shares Worth $704,821, According to a Recent SEC Filing	Mar. 15
COMPASS Pathways plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
COMPASS Pathways plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Compass Pathways Insider Sold Shares Worth $609,862, According to a Recent SEC Filing	Feb. 27
Compass Pathways Insider Sold Shares Worth $609,862, According to a Recent SEC Filing	Feb. 27
Compass Pathways Insider Sold Shares Worth $902,124, According to a Recent SEC Filing	Feb. 08
Compass Pathways Insider Sold Shares Worth $902,124, According to a Recent SEC Filing	Feb. 08
Compass Pathways Insider Sold Shares Worth $752,954, According to a Recent SEC Filing	Jan. 23
Compass Pathways Insider Sold Shares Worth $752,954, According to a Recent SEC Filing	Jan. 23
Compass Pathways plc Enters into Research Collaboration Agreement with Hackensack Meridian Health to Develop Optimal Clinical Model for Investigational Comp360 Psilocybin Treatment, If FDA-Approved	Jan. 16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages COMPASS Pathways plc

Equities

CMPS

US20451W1018

Other languages

Filters